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Despite the wide acceptance that glycans are centrally implicated in immunity, exactly
how they contribute to the tilt immune response remains poorly defined. In this study,
we sought to evaluate the impact of the malignant phenotype-associated glycan, sialyl-
Tn (STn) in the function of the key orchestrators of the immune response, the dendritic
cells (DCs). In high grade bladder cancer tissue, the STn antigen is significantly overex-
pressed and correlated with the increased expression of ST6GALNAC1 sialyltransferase.
Bladder cancer tissue presenting elevated expression of ST6GALNAC1 showed a correlation
with increased expression of CD1a, a marker for bladder immature DCs and showed
concomitant low levels of Th1-inducing cytokines IL-12 and TNF-a. In vitro, human DCs
co-incubated with STnþ bladder cancer cells, had an immature phenotype (MHC-IIlow,
CD80low and CD86low) and were unresponsive to further maturation stimuli. When contact-
ing with STnþ cancer cells, DCs expressed significantly less IL-12 and TNF-a. Consistent
with a tolerogenic DC profile, T cells that were primed by DCs pulsed with antigens derived
from STnþ cancer cells were not activated and showed a FoxP3high IFN-glow phenotype.
Blockade of STn antigens and of STnþ glycoprotein, CD44 and MUC1, in STnþ cancer cells
was able to lower the induction of tolerance and DCs become more mature.
Overall, our data suggest that STn-expressing cancer cells impair DC maturation and
endow DCs with a tolerogenic function, limiting their capacity to trigger protective anti-
tumour T cell responses. STn antigens and, in particular, STnþ glycoproteins are potential
targets for circumventing tumour-induced tolerogenic mechanisms.
ª 2014 Federation of European Biochemical Societies.
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M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 4 ) 1e1 321. Introduction MHC; costimulatory molecules, such as CD80 and CD86 andThe sialyl-Tn (STn) antigen is one of the most common
tumour-associated carbohydrate antigen, expressed by more
than 80% of human carcinomas but rarely observed in normal
tissues (Cao et al., 1996). STn is a posttranslational modifica-
tion of cell surface glycoproteins commonly resulting from
the overexpression of the ST6GALNAC1 sialyltransferase.
This enzyme transfers a sialic acid to the O-6 position of N-
acetylgalactosamine residue linked to a serine or a threonine
(GalNAca-O-Ser/Thr) on a given protein, blocking the typical
elongation of O-glycosidic chains in glycoproteins. STn
expression in cancer is associated with adverse outcome
and decreased overall survival of the patients (Itzkowitz
et al., 1990; Werther et al., 1996). It has been reported that
STn expression by cancer cells is associated withmanymalig-
nant features such as invasiveness (Julien et al., 2012; Pinho
et al., 2007), and with epithelial to mesenchymal transition
(Lin et al., 2009), a loss of cell differentiation that is an impor-
tant milestone towards cancer metastasis.
STn is highly expressed in high-grade bladder tumours,
which present elevated proliferation rates and high risk of
recurrence/progression. In bladder cancer, STn enhances
motility and invasive capacity of the cancer cells, thus being
associated with malignancy (Ferreira et al., 2013).
The expression of STn is clinically relevant, not only as a
marker for diagnosis and prognosis in cancer (the CA72-4
serological test), but also as target for therapeutic strategies.
One example is a vaccine consisting of STn-clustered epi-
topes, Theratope, that has been meaningfully used in clinical
trials to immunize breast cancer patients (Adis International,
2003; Holmberg and Sandmaier, 2004; Julien et al., 2012). Other
STn-based vaccines have also been developed for application
in clinical trial, which includes multi-epitope vaccines con-
taining STn and other tumour-associated carbohydrates and
STn-expressing glycopeptides (Heimburg-Molinaro et al.,
2011; Madsen et al., 2013; Niederhafner et al., 2008; Slovin
et al., 2007). Nevertheless, STn-based vaccines have had
limited success (Miles et al., 2011) probably because the path-
ophysiological role of STn-epitopes in cancer cells remains
unclear. One of the factors that has been highlighted by
many authors is the low immunogenicity of STn-based vac-
cines (Julien et al., 2012; Lakshminarayanan et al., 2012;
Monti et al., 2004). Thus, the elucidation of the immunemech-
anisms affected by the expression of STn by cancer cells will
contribute to improve anti-STn immunotherapy approaches.
Glycans are involved in multiple biological functions, con-
trolling many features of the immune response. In fact the di-
versity of glycans and of glycan-recognizing receptors, known
as lectins, is highly regulated by the immune cells. One of the
examples is the modulation of dendritic cell (DC) functions by
changes of their glycan phenotype during differentiation and
maturation (Crespo et al., 2009; Videira et al., 2008).
DCs play a unique and decisive role in tumour immunity,
being capable of activating antigen-specific T cells against
cancer cells (Banchereau and Steinman, 1998). To efficiently
prime T cells, DCs undergo maturation, which includes the
downregulation of the antigen-uptakemachinery, the upregu-
lation of antigen presenting molecules, class I and class IIPlease cite this article in press as: Carrascal, M.A., et al., Sial
phenotype in innate and adaptive immune cells, Molecular Oncothe synthesis of immune-enhancing cytokines (Langenkamp
et al., 2000). However, the degree of DC maturation is depen-
dent on the type of stimulus and tumour cells usually prevent
maturation, through many immunosuppressive strategies
employed in situ. Tumours render DC tolerogenic and bias
the immune response in favour of their own progression
(Almand et al., 2001; Vicari et al., 2002). The presence of imma-
ture DCs at tumour sites is consistent with DC involvement in
the tumour progression, most likely by inducing immune un-
responsiveness, i.e. tolerance against cancer (Almand et al.,
2001). We have previously reported, in bladder cancer tissue,
that the lower expression of markers of DC maturation, such
as MHC-II, was correlated with risk for recurrence (Videira
et al., 2009a). Tumour-residing DCs showing limited matura-
tion or anergy, hold back strategies to induce immune re-
sponses and create one important obstacle to the efficacy of
immune-based-therapies. Concordantly, in bladder cancer
tissue, lower levels of mature DCs are associated with low re-
sponses to the Bacillus Calmette-Guerin (BCG) immunotherapy,
the gold standard treatment for the prophylaxis and manage-
ment of non-muscle invasive bladder cancer (Beatty et al.,
2004; Videira et al., 2009a).
It has been described that STn epitope may confer, to
different cancer cell, protection from immune defence thus
contributing to malignant phenotype and cancer progression
(Monti et al., 2004; Ozaki et al., 2012). Mucins, and in particular
STnþ MUC1 mucins released by cancer cells inhibited DC
maturation andmodulate DCs towards IL-10high IL-12low regu-
latory antigen presenting cells with a limited capacity to
trigger protective T helper type 1 (Th1) responses (Monti
et al., 2004). Interestingly, soluble aberrantly glycosylated
MUC1 has also been described to elicit maturation, yet unable
to promote Th1 responses (Carlos et al., 2005). While the effect
of glycoproteins secreted by tumours is becoming more eluci-
dated, the role of the overall STn expression at tumour cell
surface in immunomodulation, remains unknown. Therefore,
in this study, we further investigated the influence of STn
expression by bladder cancer cells on the immune potency
and functionality of human DCs.2. Material and methods
2.1. Reagents
Fluorescently-conjugated or unlabelled anti-CD14 (M5E2), anti-
CD80 (2D10), anti-CD86 (IT2.2) andanti-CD45 (HI30)monoclonal
antibodies (mAbs) were purchased from BD Biosciences (San
Jose, CA). Anti-MHC-II (L243) and anti-CD1a mAb (HI149) were
from Miltenyi Biotec (Bergisch Gladbach, Germany). As anti-
STn, we used the HB-STn1 mAb from Dako (Dako Cytomation,
Denmark) or clone TKH2 (Kjeldsen et al., 1988). Clone HMFG-2
was used as anti-MUC1 (Griffiths et al., 1986). Interleukin (IL)-4
and Granulocyte-Macrophage Colony-Stimulating Factor (GM-
CSF) were purchased from R&D Systems (Minneapolis, MN).
Sialidase from Clostridium perfringenswas from Roche Diagnos-
tics (Basel, Switzerland) and carboxi-fluorescein diacetate suc-
cinimidyl ester (CFSE) from Molecular Probes (Leiden, Theyl Tn-expressing bladder cancer cells induce a tolerogenic
logy (2014), http://dx.doi.org/10.1016/j.molonc.2014.02.008
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MO, USA) unless otherwise stated.
2.2. Patient and tissue specimens
This study involved 49 patients, from Hospital S~ao Jose in Lis-
bon, who underwent transurethral resection of the bladder tu-
mours. Matched pairs of histologically verified bladder
tumours and normal appearing mucosa remote from the
tumour were collected and analysed individually. Based on
urothelial carcinoma grading and staging criteria of theWorld
Health Organization 132 (WHO), three different groups were
considered (Table 1), low-grade (LG, n ¼ 22) and high-grade
HG non muscle-invasive (NMIBC, n ¼ 21) and muscle-
invasive (MIBC, n ¼ 6) bladder cancers. None of these patients
had received prior adjuvant therapy. Patientswith carcinoma in
situ (CIS) were not included, as well as patients with presence
of upper tract malignancy, other malignancies, and chronic
infections, women expectant or lactating and patients with
congenital or acquired immunodeficiency. Prior patient con-
sent and approval from the institute research ethics commit-
tee were obtained.
2.3. Histological analysis
The immunohistochemical analysis was performed in auto-
mated equipment (Ventana BenchMark ULTRA). All reagents
were from Ventana, USA, unless otherwise stated. Briefly, the
slides were heated at 72 C, deparaffinized with EZ Prep and
antigenic recovery at 97 C. Endogenous peroxidase was
blocked with 3% of hydrogen peroxide and the slides were
incubated with TKH2 mAb (1:10). This was followed by ampli-
fication with HRP UltraView Universal Multimer, revelation
with UltraView Universal DAB Chromogen and DAB H202
and the intensification was achieved with UltraView Univer-
sal DAB Copper. The nuclear contrast was performedwith he-
matoxylin and bluing. After the immunohistochemical
technique, the slides were washed, dehydrated, treated with
increasing concentrations of alcohol (75%, 90% and 99%) for
1 min each, cleared in xylene and mounted with synthetic
mounting medium (Quick-D-M-Klinipath). A semi-
quantitative approach was established to score STn expres-
sion based on the percentage of tumour that stained positively
in comparison to the tumour bulk. The STn expression was
assessed double-blindly by two independent observers and
validated by an experienced pathologist. Whenever there
was a disagreement, the slides were reviewed, until a







Total number of cases 49
Muscle invasive (MIBC) 6 65.1 (56e79)
Non muscle invasive (NMIBC)
High grade 21 68.7 (47e84)
Low grade 22 69.9 (55e90)
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Monocytes were isolated by positive selection using anti-CD14
coated magnetic beads (Miltenyi Biotech, Germany) from pe-
ripheral blood mononuclear cells (PBMCs) of healthy volun-
teers, provided and ethically approved by the Portuguese
Blood Institute. Monocytes were differentiated into immature
mo-DCs (mo-DCs) as described (Videira et al., 2008).Whenever
needed, maturation of mo-DCs (mmo-DCs) was induced, at
day 5, with 1 mg/ml of lipopolysaccharide (LPS), for 24 h.
2.5. Flow cytometry
Cell purity, differentiation and maturation of mo-DCs was
assessed by staining with fluorescein isothiocyanate (FITC)-
labelled mAbs against CD14, BDCA-1, CD80 and CD86 or Allo-
phycocyanin (APC)-labelled anti-HLA-DR. Unlabelled mouse
anti-STn, -CD44 or -MUC1, followed by anti-mouse Ig-FITC
were used to characterize MCR cells. Flow cytometry acquisi-
tion was performed, using a FacsCalibur Flow Cytometer. File
data was analysed using the CELL QUEST (BD Biosciences) and
FLOWING (Turku, Finland) software to discriminate specific
populations, and to determine the mean fluorescence inten-
sity (MFI) of the cells.
2.6. Cell lines
The human bladder cancer cell line variants, MCRcont and
MCRSTn, were generated as described (Ferreira et al., 2013)
and were grown in Dulbecco’s modified Eagle medium
(DMEM) (Sigma), supplemented with foetal bovine serum,
glutamine, penicillin and streptomycin.
2.7. Confocal laser scanning microscopy
Cells were cultured in cover glasses, fixed with 3.7% parafor-
maldehyde and permeabilized with 0.1% TritonX-100. After
blocking with 1% bovine serum albumin (BSA), cells were
stained using anti-STn, clone TKH2, or anti-ST6GALNAC1,
clone 2C3 (Marcos et al., 2011), followed by fluorescent poly-
clonal anti-Ig antibody. The cell nuclei were stained with 1 mM
TO-PRO-3 dye (Molecular Probes, Leiden, Netherlands). Images
were acquired with a Leica TCS SP2 AOBS confocal microscope
(Leica Microsystem, Mannheim, GmbH). Representative
confocal cross-section images were selected after Z-stacking.
2.8. Establishment of DC: bladder cancer cell lines
cocultures
Cancer cell lineswere incubated at 0.2 106 cells/ml in a 6-well
plate, at 37 C. After 24h,mo-DCswere added in theproportion
of 1:5 (cancer cell: mo-DC) in adhesion buffer (20 mmol/l of
trizma hydrochloride, 150 mmol/l of sodium chloride,
1 mmol/l calcium chloride, 1 mmol/l magnesium chloride
and 0.5% BSA, pH 8.0) at 37 C. After 2 h incubation, the non-
adherent mo-DCs were washed and the coculture of MCR
with adherent mo-DCs was stained with mAbs against MHC-
II, which is expressed by DCs, but not by MCR cell lines, thus
allowing to assess the percentage of adhering mo-DCs in the
coculture. The cell viability was measured by annexin-Vyl Tn-expressing bladder cancer cells induce a tolerogenic
logy (2014), http://dx.doi.org/10.1016/j.molonc.2014.02.008
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buffer without calcium or magnesium, to assess the impact
of divalent ions. In other experiments,mo-DCswere incubated
with 24 h supernatants obtained from MCR cell cultures to
assess the requirement for cell: cell interactions.When testing
function blocking mAb, to avoid unspecific Fc receptor-
mediated mAb binding to mo-DCs, the Fc receptors from mo-
DCs were blocked with 10% human serum. In addition, the
blocking antibodies were added to the MCR cells and not to
mo-DCs. We used 20 mg/ml of anti-CD44 mAb (clone IM7),
1:100 of anti-STn mAb (clone HB-STn1), 1:20 of anti-MUC1
(clone HMFG-2) or isotype control for 30 min, washed and
then cocultured the mAb coated MCR cells with mo-DCs, as
described above.
2.9. Gene expression analysis by real-time PCR
RNA extraction from formalin-fixed, paraffin embedded sec-
tions was performed after deparaffinization of tissues, using
Absolutely RNA FFPE kit (Agilent technologies) while RNA
from the cocultures was isolated using the GenElute Mamma-
lian Total RNA Purification kit (Sigma), according to the man-
ufacturer’s instructions. After DNAase treatment, 1 mg of total
RNA was reverse transcribed with random primers and the
real-time PCR was performed with Master Mix, TaqMan
probes and primers from Applied Biosystems. The assay ID
provided by themanufacturer were: Hs00300842_m1 (ST6GAL-
NAC1); Hs00168405_m1 (IL-12a); Hs00174128_m1 (TNF-a);
Hs00174086_m1 (IL-10); Hs00372324_m1 (IL-23),
Hs00203958_m1 (FoxP3) and Hs00174143_m1 (IFN-g). The rela-
tive mRNA levels were normalized against the arithmetic
mean of the b-actin and GAPDH expression and calculated by
adapted formula 2DCt  1000 which infers the number of
mRNA molecules of the gene of interest per 1000 molecules
of the endogenous controls (Videira et al., 2009b). DCt stands
for the difference between the cycle threshold of the target
gene and that of the endogenous control genes. The efficiency
for each primer/probe was above 95% (as determined by the
manufacturer). When analysing the gene expression of mo-
DCs in the coculture, the contamination with MCR cells was
disregarded since the analysis of cytokine gene expression
in both MCR cell line variants showed a completely absence
of IL-12a, TNF-a, IL-10, IL-23, FoxP3 and IFN-g gene expression.
2.10. Phagocytosis assay
Cell lines were labelled with CFSE according to the manufac-
turer’s instructions and then induced to apoptosis with
10 mM of camptothecin. After 48 h, cells were incubated with
mo-DCs in the proportion of 1:2, in a 48-well plate, for 6 h at
37 C or 4 C. After incubation, cells were stained with anti-
MHC-II mAb and the percentage of MHC-IIþ/CFSEþ cells (mo-
DCs that phagocytosed MCR cells) was calculated by flow
cytometry and confirmed by confocal microscopy. The values
obtained at 4 C were subtracted from the 37 C values.
2.11. T cell activation
Human T cells were obtained during monocyte isolation pro-
cedure (CD14 PBMC fraction) and maintained in completePlease cite this article in press as: Carrascal, M.A., et al., Sial
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gous T cells were then incubated with mo-DCs following
phagocytosis of MCR cells, as described above, in the propor-
tion of 8:1, in a 96-well round bottom plate, throughout 11
days. As controls, similar experiments were performed with
unstimulated mo-DC or with the MCR cell lines (negative con-
trols) or with phytohaemagglutinin (positive control). T cell
activation was assessed by the percentage of CD69þ cells
within the CD3þ population (T cells) and their MFI values
were evaluated by flow cytometry.
2.12. Protein extraction, immunoprecipitation and
western blotting
Proteins were isolated from cell lines using RIPA buffer (Sig-
maeAldrich) and bladder tumour proteins were extracted
from formalin-fixed paraffin embedded tissues using the
Qproteome FFPE tissue kit (Qiagen). The amount of protein
was estimated with RC protein assay kit (BioRad). CD44 pro-
tein was immunoprecipitated from total protein extracts (IP)
with anti-CD44 monoclonal antibody (2C5 clone; R&D Sys-
tems) using Pierce Direct IP Kit (Thermo Scientific). Protein
samples were separated in reducing SDS-PAGE gels, using
20 mg per lane, transferred to 0.45 mmnitrocellulosemembrane
(GE Healthcare Life Sciences) and blocked with 1% Carbo-Free
Blocking Solution (Vector Laboratories). TKH2 and goat anti-
mouse IgG1 heavy chain horseradish peroxidase conjugate
(Abcam) were used as primary and secondary antibodies,
respectively. The Amersham ECL Prime Western Blotting
Detection Reagent (GE Healthcare Life Sciences) was used as
developing reagent. Protein extracts treated with sialidase
were used as controls.
2.13. Statistical analysis
Statistical analyses were conducted using GraphPad Prism
software, version 5.0 (GraphPad Software, La Jolla, CA). Paired
student’s t-test was usedwhen datawas normally distributed,
and the results expressed as the mean values SDs. Alterna-
tively, Wilcoxon signed-rank test was used in the case of
non-normal distribution, and the results were plotted individ-
ually or as box and whiskers plot. The correlations were ana-
lysed using Spearman and Pearson methods. Tests were
considered statistically significant when p < 0.05 (*), p < 0.01
(**) and p < 0.005 (***) andmarginal significance was considered
for p < 0.1.3. Results
3.1. The STn antigen expression and DCs are increased
in bladder cancer
We have previously reported that STn is highly overexpressed
in bladder cancer tissues, showing a markedly high incidence
and intensity only in malignant tissue and was barely detect-
able in normal mucosa (Ferreira et al., 2013) (Figure 1A).
Considering the tumour bulk the maximum STn expression
was 30%. The STn expression is highly correlated with the
gene expression of the sialyltransferase ST6GALNAC1yl Tn-expressing bladder cancer cells induce a tolerogenic
logy (2014), http://dx.doi.org/10.1016/j.molonc.2014.02.008
Figure 1 e Bladder cancer tissues show differential expression of STn antigen, CD1a, IL-12 and TNF-a cytokines. A: Analysis of STn expression
in high grade tumour bladder cancer tissue. Representative image of a paraffin embedded section, processed for immunohistochemical staining
with anti-STn mAb. STn expression was detected in tumour tissue. B: Association between ST6GALNAC1 and STn expression in bladder
tumours. STn expression was determined in low and high grade bladder tumours, by immunohistochemistry, using TKH2 mAbs. Specimens were
then selected and distributed into three groups, according to their expression of STn related with the tumour bulk: 0%, 0e15% and more than 15%
of tissue expressing STn. The relative mRNA levels of ST6GALNAC1 gene, in the paraffin-embedded sections, was analysed individually, by real
time PCR and paired compared with data regarding STn expression. Values infer the number of mRNA molecules of a ST6GALNAC1 gene, per
1000 molecules of the average of the endogenous controls. C: Gene expression analysis in bladder tissue. The relative mRNA levels of CD1a, IL-12
and TNF-a cytokines and ST6GALNAC1 genes were analysed by real time RT-PCR in specimens from low and high grade non-muscle invasive
bladder cancer (NMIBC) (n [ 22 and n [ 21, respectively) and muscle invasive bladder cancer (MIBC) (n [ 6) tissues and also from matched
normal urothelium (n [ 49). Values infer the number of mRNA molecules of each gene per 1000 molecules of the average of the endogenous
controls. CD1a and ST6GALNAC1 expression was significantly increased in all tumour tissue, as compared with matched urothelium; while IL-12
and TNF-a cytokines were decreased ( p< 0.05 (*) and p< 0.01 (**)). In general, the differences were more evident in high grade NMIBC.
M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 4 ) 1e1 3 5(Figure 1B) either in low and high grade tumours. To assess
whether STn expression was correlated with altered immune
function, we quantified the expression of ST6GALNAC1 and
CD1a, a marker for immature DC subtype predominant in
bladder carcinoma (Figure 1S) (Troy et al., 1999). We also
investigated the expression of interleukin (IL)-12, and tumour
necrosis factor (TNF)-a, cytokines naturally expressed by DCs
and involved in inducing Th1-immune responses. We have
analysed tumour tissue and adjacent normal urothelium,
and our data showed that both CD1a and ST6GALNAC1 are
upregulated in tumour tissue, as compared with correspond-
ing normal urothelium. Interestingly, the upregulation was
more pronounced and significantly correlated in muscle inva-
sive and high grade non muscle invasive tumours rather than
low grade tumours (Figure 1C). By contrast IL-12 and TNF-a
expression, which is associated with DC maturation and
Th1-inducing, showed an inverse correspondence withPlease cite this article in press as: Carrascal, M.A., et al., Sial
phenotype in innate and adaptive immune cells, Molecular Oncosignificantly lower expression in high grade tumour tissue
than low grade tumour tissue. A correlation was observable
between CD1a and ST6GALNAC1 (r ¼ 0.41 and p ¼ 0.003)
expression, pointing out for an association between STn
expression by cancer cells and the presence of immature
DCs in tumour tissue.
3.2. Mo-DCs tend to adhere to STnþ bladder cancer cell
lines and show significant less mature phenotype
To further investigate the functional implications of STn-
expressing cancer interaction on DC functionality, we estab-
lished in vitro coculture models with STnþ bladder cancer
cell lines and human mo-DCs. The transduction of ST6GAL-
NAC1 sialyltransferase cDNA in MCR bladder cancer cell lines,
that natively do not express STn, induced a dramatic expres-
sion of STn (Figure 2A), corroborating the role of ST6GALNAC1yl Tn-expressing bladder cancer cells induce a tolerogenic
logy (2014), http://dx.doi.org/10.1016/j.molonc.2014.02.008
Figure 2 eMo-DCs adhere preferentially to STnDMCRcell line and show a less mature phenotype. A: Overexpression of ST6GALNAC1 inMCR
bladder cancer cells. MCR cells were transduced or not with a retroviral vector expressing the whole coding region of human ST6GALNAC1. Both
negative control (MCRcont) and ST6GALNAC1-transduced (MCRSTn) cell lines were stained with anti-STn or anti-ST6GALNAC1 mAbs and
then analysed by confocal microscopy. The MCRSTn cell line, but not MCRcont cells expressed the STn antigen and ST6GALNAC1. B:
Characteristics of mo-DCs adherent to MCR cell lines. Mo-DCs were cocultured with MCR cell lines and after 2 h incubation, non-adherent mo-
DCs were washed and the percentage of mo-DCs adherent to MCR cell lines was estimated by flow cytometry, as the total of MHC-IID cells in the
coculture, following stainingwithAPC-labelled anti-MHC-IImAb.Themean number ofmo-DCs adhering toMCRcells was significantly higher in
the co-incubation with MCRSTn than with MCRcont ( p[ 0.045 (*), n[ 14). C-E: Analysis of mo-DC maturation and co-stimulatory profile.
Adherent mo-DCswere stained with anti-MHC-II (C), anti-CD80 (D) or CD86 (E)mAbs and then analysed by flow cytometry. The expression level
of the antigens was inferred from the mean fluorescence intensity (MFI) of the cells. Values are displayed as box-and-whisker plot with mean and
quartiles ± maximum/minimum of 5 independent assays. The expression of MHC-II and CD80 was significantly different in mo-DCs co-incubated
withMCRSTn, as compared withMCRcont ( p[ 0.0043 (**) and p[ 0.0438 (*), respectively).MFI values in mo-DCs alone were comparable tomo-
DCs co-incubated with MCRSTn, while mo-DCs co-incubated with MCRcont showed a significant more mature phenotype.
M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 4 ) 1e1 36in STn biosynthesis by bladder cancer cells (Ferreira et al.,
2013). The obtained STnþ (MCRSTn) and mock transduced
STn (MCRcont) cell lines were used throughout this study.
Co-incubation of human mo-DCs together with MCR cells
showed that a significant number of mo-DCs adhered to the
cancer cells. The mean percentage of adhering mo-DCs was
significantly higher in the coculture with MCRSTn (1.27-fold
more) than with MCRcont (Figure 2B). We also investigate
whether the observed cellular interactions were dependent
on divalent ions, a characteristic of many intercellular inter-
actions. In the absence of divalent ions, mo-DC adhesion to
bladder cancer cells was reduced to an average of 10%
adherent cells and it was not statistically different between
the cocultures with each of two cell line variants (data not
shown), suggesting that the differences in adhesion of mo-
DCs to MCR cells were dependent on divalent cations.
To characterize the maturation phenotype of the mo-DCs
adhering to the bladder cancer cells we assessed the expres-
sion of the MHC-II antigen presenting molecule, and co-
stimulatory molecules, CD80 and CD86. While the mo-DCs
co-incubated with MCRcont cells showed increased expres-
sion of MHC-II, CD80 and CD86, mo-DCs adhering to MCRSTnPlease cite this article in press as: Carrascal, M.A., et al., Sial
phenotype in innate and adaptive immune cells, Molecular Oncopresented an expression level similar to the non-stimulated
mo-DCs, suggesting that no maturation was induced
(Figure 2C, D and E). To verify whether the immature pheno-
type of mo-DCs incubated with MCRSTn was dependent on
cell contact, parallel experiences were performed where mo-
DCs were incubated in the presence of conditionedmedia, ob-
tained from MCRcont or MCRSTn cell cultures. However, in
these conditions the phenotype of mo-DCs incubated with
the conditionedmedium fromeitherMCR variantswas similar
(data not shown). The viability of the mo-DCs in culture was
approximately 97%, indicating that the observed differences
in adhesion and maturation were not due to loss of mo-DC
viability. Effects on the MCR cells was also observed, but only
when the cocultures were prolonged until 24 h. Specifically,
we observed that the proliferative capacity of MCRSTn cells
increased 26% ( p ¼ 0.007), as compared with the proliferative
capacity of this cell line in the absence of mo-DCs (Figure 2S).
In order to confirm that the effects on maturation and
adhesion tomo-DCs were specifically caused by the enhanced
expression of STn, the adhesion assayswere performedwith a
different cell line, namely the breast cancer cell line, MDA-
MB-231STn, overexpressing the STn antigen (Julien et al.,yl Tn-expressing bladder cancer cells induce a tolerogenic
logy (2014), http://dx.doi.org/10.1016/j.molonc.2014.02.008
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more to MDA-MB-231STn cells when compared to control
cells, and these mo-DCs expressed significantly less MHC-II
on their surface, showing a less mature phenotype
(Figure 3S). Therefore, the same negative effects is obtained
after co-incubation of mo-DCs with STnþ cancer cells, irre-
spective of the cancer type, corroborating the immunomodu-
latory role specifically for STn.
We then investigated theeffect of STnþ cancer cells in semi-
matured mo-DCs. We stimulated mo-DCs with LPS, a canoni-
cal inducer of mo-DCmaturation, which resulted in a remark-
able increase of MHC-II expression by DCs (Figure 4SA). In our
conditions, LPS-matured DCs could still respond to secondary
maturation stimuli and were therefore referred semi-mature.
We observed that semi-matured mo-DCs adhere significantly
less to both MCRcont and MCRSTn, when compared with
immature mo-DCs (55% and 61% less, respectively, data not
shown). After co-incubation of semi-matured mo-DCs with
MCRcont, a significant increased expression of MHC-II was
observed ( p ¼ 0.043), while no significant effect was obtained
by a parallel incubation with MCRSTn cells (Figure 4SA).
To assess whether the contact with MCR cancer cells influ-
enced further mo-DC responses to maturation stimulus, we
stimulated mo-DCs with LPS, after coculture with MCR cells.
In the presence of the cancer cells, mo-DCs showed defective
LPS-induced maturation, while in their absence mo-DCs un-
derwent maturation (Figure 4SB). The resistance to matura-
tion was more evident when mo-DCs were previously
incubated with MCRSTn, as compared with MCRcont cancer
cells. Thus, the data suggest that the contact with STnþ
bladder cancer cells not only hindersmaturation, but also pre-
vents further mo-DC maturation.3.3. Contact with STnþ cancer cells compromises mo-DC
cytokine expression and phagocytosis
Next, we investigated the function of mo-DCs following con-
tact with STnþ cancer cells. We analysed the expression of
several cytokine genes and found that the expression of IL-
12, TNF-a, IL-23 and IL-10 was significantly decreased in mo-Figure 3 e Co-incubation with STnDMCR cell line downregulates cytokin
10 cytokine genes was evaluated by quantitative real-time PCR. The relative
the expression of the endogenous positive controls. Values represent the me
IL-23 and IL-10 were significantly decreased ( p[ 0.015 (*), p[ 0.031 (*),
with MCRSTn as compared with those incubated with MCRcont.
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(Figure 3A). Analysis of the level of phosphorylated extracel-
lular signal-regulated kinase (ERK), which is involved in cyto-
kine expression, was reduced by 21% in mo-DCs following
contact with MCRSTn cells (data not shown).
Since mo-DCs physiologically phagocyte apoptotic cancer
cells, we then compared the capacity of mo-DCs to phagocyte
both MCR cancer cell line variants. As shown in Figure 4A and
B, the percentage of mo-DCs which phagocytosed MCRSTn is
significantly higher (1.25-fold more) than those that phagocy-
tosed MCRcont. Confocal microscopy analysis confirmed the
internalization of MCRSTn cells by mo-DCs (Figure 4B).3.4. T cells activated with mo-DC loaded with STnþ
cancer cells show defective activation profiles
We next analysed the capacity of mo-DCs to activate autolo-
gous T cells by measuring the expression of the T cell activa-
tion marker CD69. We observed that the mo-DCs that
phagocytosed MCRSTn tended to activate significantly less
number of T cells, and more weakly, than mo-DCs phagocy-
tosing MCRcont (Figure 5A and B). T cell activation was also
lower in T cells primed by mo-DCs that adhered to STnþ can-
cer cells (Figure 5S), as compared to control MCR cells. T cells
alone and T cells incubated with each apoptotic MCR cell
lines (with no mo-DCs) were not significantly activated and
lost viability (less than 5% viable cells after 11 days). By
contrast, after 11 days, more than 35% of the T cells cocul-
tured with mo-DCs remained viable, suggesting that mo-
DCs stimulus is necessary to maintain T cell viability. Inter-
estingly, in the T cell: mo-DC (MCRSTn) coculture, the expres-
sion of interferon (IFN)-g and the transcription factor
forkhead box P3 (FoxP3) was significantly affected. Namely,
IFN-g was decreased by 54%, while FoxP3 was increased
39% compared with control (Figure 5C and D). While the dif-
ferences were marginally significant ( p < 0.1), they indicated
a clear tendency for less Th1-skewed T cell response. These
data are in agreement with the above mentioned defective
maturation profile of mo-DCs, following contact with STnþ
cancer cells.e expression levels. A: The expression of TNF-a, IL-23, IL-12 and IL-
mRNA levels for each cytokine are expressed as the permillage (&) of
ans of at least 5 independent assays. The expression of TNF-a, IL-12,
p[ 0.034 (*) and p[ 0.015 (*) respectively) in mo-DCs co-incubated
yl Tn-expressing bladder cancer cells induce a tolerogenic
logy (2014), http://dx.doi.org/10.1016/j.molonc.2014.02.008
Figure 4 e STnDMCR cell lines are better phagocytosed by mo-DCs. Both MCRcont and MCRSTn cell lines were labelled with CFSE and then
induced to apoptosis. Cells were then incubated with mo-DCs to allow phagocytosis, in the proportion of 1:2 for 6 h at 37 C or 4 C and then
stained with anti-MHC-II mAb. A: Flow cytometric analysis of percentage of mo-DCs that phagocytosed MCR cells lines. The percentage of mo-
DCs that phagocytosed MCR cells was calculated based on the positivity for both MHC-II and CFSE staining. The values obtained at 4 C were
subtracted from the 37 C values. MCRSTn cells were significantly more phagocytosed than MCRcont ( p [ 0.001 (**), n [ 4). B: Microscopic
analysis of mo-DCs that phagocytosed MCR cells lines. Representative confocal microscopy image showing mo-DCs that phagocytosed MCRSTn
cells [MHC-IID (red)/CFSED (green)]. The image is representative of a confocal cross-section image, selected from Z-stack images.
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MUC1 and CD44 are glycoproteins equally expressed by both
MCR cells (Figure 6A and B) and described as the most likely
candidates for being modified by STn by human cancer cells
(Julien et al., 2006). The Western blot analysis of MCRSTn cell
lysates, using anti-STn mAb, identified one prominent band
of approximately 75 KDa, and two weak bands of 150 KDa
and 260 KDa each. In all cases, the blot staining was
completely abolished after sialidase treatment, proving the
STn staining specificity. Immunoprecipitation assays led us
to identify the most prominent band (75 KDa) as CD44.
Bladder tumours also showed STn in CD44 proteins, as
shown by the detection of a STnþw75 KDa band in the West-
ern blot analysis (Figure 6C). In order to confirm the role of
the STnþ protein scaffold, we blocked STnþ glycoproteins in
MCRSTn cells and conducted coculture assays with mo-DCs
similar to those described above. In the cocultures, whenever
the CD44 was blocked in the MCRSTn cells, they gained the
capacity to significantly increase, in mo-DCs, the expression
of MHC-II and cytokines, in particular of IL-12 and TNF-a
(Figure 6D). Blocking of MUC1, as well as STn antigen in
MCRSTn cells also upregulated MHC-II and cytokine expres-
sion, indicating a tendency, although not statistically signifi-
cant (Figure 6D).4. Discussion
We have recently reported that the majority of high-grade
bladder tumours, presenting elevated proliferation indexes
and high risk of recurrence/progression and invasion,
expressed STn (Ferreira et al., 2013). This glycan is not
expressed by normal epithelium and it has been associated
with a poor prognosis, and the invasive capacity of thePlease cite this article in press as: Carrascal, M.A., et al., Sial
phenotype in innate and adaptive immune cells, Molecular Oncotumours (Ferreira et al., 2013). Similar observations were
made for breast and gastric cancers and other solid tumours,
supporting theubiquitous associationof STnwithmalignancy.
The expression of the STn antigen is also accepted to be
implicated in the immunogenicity of cancer cells and this
has been explored in STn-based vaccines to induce protective
immune responses against STnþ cancers. Humoral immune
responses against STn have been reported in vaccinated pa-
tients and mouse models (Holmberg and Sandmaier, 2004;
Julien et al., 2009), demonstrating that the immune system re-
acts against STn antigens. However, the potency of the im-
mune response is not clinical relevant to provide patients
with robust anti-tumour protection.
While, glycans are known to be implicated in several im-
mune responses, the involved biological processes are diverse
and complex and thus still poorly understood. Lectin-glycan
ligand interactions are implicated not only in mechanisms
that establish immune protection, but also in those that estab-
lish immunological tolerance. Given the clinical relevance of
STn antigens, a deeper investigation on the interaction of
STn expressing cancer cells with the immune system is war-
ranted to improve and develop novel STn-based therapeutics.
Here we have studied the influence of STn antigen in the
modulation of DCs, which are recognized by their pivotal
role in the definition of immune responses. In the tumour tis-
sue, we observed a significant correlation between STn
expression and an immature profile of DCs. Indeed, the
expression of ST6GALNAC1, which is correlated with the
expression of the STn epitopes, in bladder cancer, is correlated
with CD1a, a marker of immature DCs. Interestingly, high
grade bladder tumours presented not only higher levels of
ST6GALNAC1 and CD1a, but also lower levels of the pro-
inflammatory, Th1-inducing cytokines, IL-12 and TNF-a,
thus supporting the association between STn and DC imma-
ture profile.yl Tn-expressing bladder cancer cells induce a tolerogenic
logy (2014), http://dx.doi.org/10.1016/j.molonc.2014.02.008
Figure 5 e T cell activation is reduced when primed with mo-DCs that phagocytosed STnD cancer cells. Mo-DCs were allowed to phagocytose
MCR cells and then incubated with autologous T cells (1:8 proportion). AeB: The coculture was analysed by flow cytometry for the expression of
the T cell early activation marker CD69. A: Graphical representation of the percentage of CD69D T cells. Data was determined by the percentage
of CD69D, within the CD3 population (n[ 3). Mo-DCs that phagocytosed MCRSTn cells induce significantly less activation in T cells than mo-
DCs that phagocytosed MCRcont cells ( p [ 0.026 (*)). B: A representative CD69 histogram for T cells following priming with mo-DCs that
phagocytosed MCRcont (solid line) or MCRSTn (dashed line) cell line. Expression of CD69 by resting T cells is shown as staining control (grey
filled peak). CeD: The coculture was analysed by quantitative real-time PCR regarding the expression of IFN-g and FoxP3 genes. The relative
mRNA levels for each gene are expressed as the permillage (&) of the expression of the endogenous positive controls. C: The expression of IFN-g
was reduced by 54% ( p[ 0.074) in T cells co-incubated with mo-DCs that phagocytosed MCRSTn as compared to controls (n[ 4). D: T cells
co-incubated with mo-DCs that phagocytosed MCRSTn expressed 39% ( p [ 0.081) more FoxP3 than control mo-DCs (n [ 4).
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tively prime T cells to mount responses against malignant
cells (Steinman et al., 2003). To confirm a possible inverse as-
sociation between STnþ cancer cells and DC maturation and
to investigate if STn antigen played a role in DC maturation,
we used in vitro models of STnþ cancer cells cocultured with
human DCs. We have found that DCs tend to adhere more
to STnþ cancer cells and that this contact inhibits DCmatura-
tion and co-stimulation, when compared with DCs cocultured
with STn- control cells. The higher cell adhesion to STnþ can-
cer cells, which could be due to either stronger or longer cell
contacts, was responsible for the defective maturation of
mo-DCs. After coculture with STnþ cancer cells, the lower
expression of MHC-II and of co-stimulatory molecules could
not be rescued by LPS stimulation, suggesting that mo-DC
become resistant to further maturation stimuli.Please cite this article in press as: Carrascal, M.A., et al., Sial
phenotype in innate and adaptive immune cells, Molecular OncoAn hallmark of immature DCs is a high phagocytic capac-
ity, which is lowered upon maturation. In agreement with
the fact that STn-expressing cancer cells prevents thematura-
tion of mo-DCs, mo-DCs showed better phagocytic capacity
for STnþ cancer cells than for control cells. Nevertheless, the
effects seen might not only be caused by STn but also some
general feature of the MCR cells, since MCRcont cells also
induced small maturation arrest.
Mo-DCs incubated with STnþ cancer cells showed defec-
tive expression of TNF-a and IL-12, which is consistent not
only with DC immature phenotype but also with data
observed in bladder tumour tissues. These observations
were also in agreement with other reports showing that
tumour environment lowers the expression of inflammatory
cytokines by DCs (Ishida et al., 2008). We have not detected
significantly altered expression of anti-inflammatoryyl Tn-expressing bladder cancer cells induce a tolerogenic
logy (2014), http://dx.doi.org/10.1016/j.molonc.2014.02.008
Figure 6 e STnD glycoproteins blockade restoremo-DCsmaturation.AeB:MCRcell lineswere analysedbyflowcytometry regarding the expressionof
possible scaffolds of STn,CD44 andMUC1glycoproteins.MCRcont (dashed line) andMCRSTn (solid line) cell lineswere stainedwith anti-CD44 (A)
or anti-MUC1 (B)mAb (not filled peaks) or only with secondary mAb (grey filled peak) as staining control. BothMCR cell lines express similarly CD44
andMUC1 glycoproteins. C: Analysis of STnD proteins in cancer cells. Total protein lysates fromMCRSTn cell line (left image) and primary bladder
tumour samples (right image) were treated (T) or not (NT)with sialidase.CD44 immunoprecipitation (IP) fromMCRSTn total proteins was performed
using Pierce Direct IP Kit (middle image). Cell lysates and CD44 IP were separated and the proteins were transferred to nitrocellulose membrane and
stained with anti-STnmAb (cloneTKH2).MCRSTn cells showed three proteins (z75KDa, 150KDa and 260KDa) decoratedwith STn and themost
prominent STnD protein showed a molecular weight ofz75 KDa. As control, when the lysate was treated with sialidase, staining with anti-STn was
completely abrogated. TheCD44 IP analysis showed thatCD44 protein is decorated with STn inMCRSTn cells.D:The expression ofMHC-II, IL-12
andTNF-a is restoredwhenblockingSTnandSTnDglycoproteins.Gene expressionwas evaluatedbyquantitative real-timePCRinmo-DCs incubated
withMCRSTn cell line in presence of anti-CD44, -MUC1 or -STn blockingmAbs.Mo-DCFc receptors were previously blocked to avoid non-specific
Fc receptor-mediated antibody binding. The expression values were calculated as described in the Material andMethod section and correspond to the
ratio between the expression ofmo-DCs incubated withMCRSTn cell line in presence of blockingmAbs and the expression ofmo-DCs incubated with
MCRSTn inpresence of isotypic control.CD44blockadewas able to increase the expression ofMHC-II, IL-12 andTNF-a ( p[ 0.0294 (*), p[ 0.0357
(*), p[ 0.0035 (**), n[ 3). Similarly, the expression of MHC-II, IL-12 and TNF-a was also increased by MUC1 and STn blockage.
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may be a balanced consequence of the downregulation of
pro-inflammatory cytokines, playing a dual proliferative and
inhibitory effect (Ogden et al., 2005).
The negative effect of STnþ cancer cells on the maturation
and Th1-inducing profile of mo-DCs were observable in less
than 2 h of coculture. On the other hand, STnþ cancer cells
could themselves be influenced by mo-DCs. This was evi-
denced by the significant increase proliferation of MCRSTn
cells in the presence of mo-DCs that was not observable in
MCRcont cells. Yet these differences were only observable af-
ter 24 h coculture, and themechanism behind the altered pro-
liferation may be dissociated from the ones implied on the
altered mo-DC phenotype. However, in the future, the effect
of mo-DCs in tumour cell proliferation should be further clar-
ified and itmight be associatedwith the fact that STnþ bladder
tumours present elevated proliferation indexes in situ.
The fact that using other STnþ cell line, i.e., the MDA-MB-
231STn breast cancer cell line, also rendered mo-DCs with
an immature phenotype, with an extent similarly to the
phenotype induced by MCRSTn bladder cancer line, strongly
suggested that the specific STn overexpression in cancer cell
was responsible for the induction of tolerogenic DCs reported
here. Nevertheless, we cannot disregard the fact that ST6GAL-
NAC1 overexpression in cell lines also alters other glycan
structures beyond the STn (Table IS).
To further confirm the role of STn expression by cancer
cells in DC maturation, we used different strategies to abro-
gate the MCRSTn cancer cell interaction with DCs. Blocking
of STn antigen inMCR cells, bymeans of the HB-STn antibody,
described to block STn interactions (Pinho et al., 2007),
resulted in tendency of MCRSTn cells to induce DC matura-
tion. This suggested that blocking STn antigen may reverse
the propensity of STnþ cancer cells to induce tolerogenic
DCs. The fact that we were not able to obtain statistical signif-
icant differences may have to do with the role of the protein
scaffolds that also participate in the recognition or interaction
of glycans (Padler-Karavani et al., 2008). Therefore, anti-glycan
mAbs may not have efficient function-blocking properties, as
anti-scaffolds have.
We have observed that the major protein scaffold in the
MCRSTn cells and bladder tumours is CD44. Moreover CD44
is also decorated with STn in MDA-MB-231STn breast cancer
cells (Julien et al., 2006), which in this work induced the
sameDC immunomodulation asMCRSTn cells. These findings
suggested us a possible involvement of STnþ CD44 in the
acquisition of the immature profile by DCs. Concordantly,
blockade of MCR CD44 by means of functional blocking anti-
bodies was able to restore the capacity of the mo-DCs to
become matured.
CD44 is a rather ubiquitously expressed adhesionmolecule,
involved in several processes includingmigration and cell sig-
nalling and recognition. The role of CD44 in governing the pro-
gression of tumours, including bladder carcinoma (Golshani
et al., 2008), is well documented and its expression by leuko-
cytes also plays a role in modulating immune responses
(Hegde et al., 2008; Jacobs and Sackstein, 2011; Weiss et al.,
1997). However the role of its recognition by immune cells,
such as DCs, is unclear. In our model, it is possible that DC re-
ceptor for CD44 may recognize differently the protein due toPlease cite this article in press as: Carrascal, M.A., et al., Sial
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CD44 is a receptor for hyaluronic acid and other extracellular
proteins, such as osteopontin and collagens. Very recently it
has been reported that the mannose receptor interacts with
CD44 (Salmi et al., 2013). Although, mannose receptor primar-
ily binds mannose and fucose, it is possible that in our model,
the STn expression affected the CD44 recognition bymannose
receptor, leading to thedescribed immunological implications.
Nevertheless, other receptors expressed by DCs may also be
involved, such as the Sialic acid-binding immunoglobulin-
type lectins (Siglec)-9 that have also been reported to recognize
STn antigen (Ohta et al., 2010). In addition, the participation of
other STn scaffolds such as MUC1 (Monti et al., 2004) should
not be excluded and as matter of fact, we also observed that
blockade of MUC1 results in a slight induction of DC matura-
tion. Further studies are therefore necessary to better charac-
terize the mechanisms of STn antigen recognition by DCs.
As mentioned above, previous studies were controversial
in demonstrating that STn mucins were implicated in
inducing the immature DC phenotype (Carlos et al., 2005;
Monti et al., 2004). While this controversy may be due to the
complexity of the involved mechanisms, these studies were
in agreement, when showing that STn expression has a nega-
tive influence on the capacity of DCs to activate T cells, result-
ing in DCs that do not support T cell commitment to Th1
phenotype, which is important for tumour rejection (Carlos
et al., 2005; Monti et al., 2004).
DCs are currently used as anti-tumour cell-based vaccines,
where one of themost common strategies is the upload of pa-
tient’s DCs ex vivowith the tumour cell antigens (lysates, cells
fusion or apoptotic bodies). Tumour antigens are phagocy-
tosed by DCs and these cells are then used to induce anti-
tumour T cells responses and further tumour rejection
(Palucka and Banchereau, 2013). It has been reported that
DCs pulsed with apoptotic cancer cells are able to activate
cytotoxic T cells against poorly immunogenic cancer cells
(Goldszmid et al., 2003) and in bladder cancer patients in-
creases survival and cure rate (Nair et al., 1997). In the present
study, DCs pulsed with immunosuppressive STnþ cancer cells
showed a tolerogenic/regulatory profile, resistant to further
maturation stimuli and limited capacity to activate T cells.
In these conditions, mo-DCs express lower levels of Th1-
inducing cytokines and preferentially polarize T cells towards
a FOXP3high IFN-glow phenotype, typical of regulatory T cells.
On the other hand, it has been recently reported by us that
STn expression in bladder cancer is associated with better re-
sponses to complementary immunotherapy with Bacillus
Calmette-Guerin, a potent inducer of Th1 responses (Lima
et al., 2013). Therefore, the combination of Th1-inducing ther-
apies with DC-based therapy against STn-bearing cancer cells
could be a promising strategy to induce anti-tumour protec-
tive responses. Nevertheless, a better understanding of the
mechanisms behind the tolerogenic/regulatory profile of DCs
induced by STnþ cancer cells is still necessary.5. Conclusions
This study shows that STn, a cancer-associated carbohydrate
antigen expressed in high-grade bladder cancers, has theyl Tn-expressing bladder cancer cells induce a tolerogenic
logy (2014), http://dx.doi.org/10.1016/j.molonc.2014.02.008
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through differentmechanisms. First, it hinders the expression
of MHC-II and co-stimulatory molecules by DCs, resulting in
impaired ability to present cancer-associated antigens to T
cells and making DCs unresponsive to successive activation
stimuli. Second, it hinders the expression of inflammatory,
Th1-inducing cytokines in DCs, which may result in an atten-
uation of the Th1 microenvironment. Third, DCs pulsed with
STn-expressing cancer cells show a reduced ability to activate
and polarize T cells towards the Th1 phenotype, resulting in
impaired ability to mount an effective anti-tumour response.
Finally, blockade of STn antigens and STn proteinmay reverse
tolerance induced by cancer cells. Altogether, these results
highlight the expression of STn by cancer cells as a crucial
event in the establishment of the tolerogenic microenviron-
mentwhich allows cancers to escape from the attack of innate
and adaptive immunity.Acknowledgements
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